+

WO2001003774A3 - Composition pharmaceutique de traitement de la calcification - Google Patents

Composition pharmaceutique de traitement de la calcification Download PDF

Info

Publication number
WO2001003774A3
WO2001003774A3 PCT/HU2000/000053 HU0000053W WO0103774A3 WO 2001003774 A3 WO2001003774 A3 WO 2001003774A3 HU 0000053 W HU0000053 W HU 0000053W WO 0103774 A3 WO0103774 A3 WO 0103774A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
calcification
treatment
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Application number
PCT/HU2000/000053
Other languages
English (en)
Other versions
WO2001003774A2 (fr
Inventor
Zoltan Dardai
Original Assignee
Zoltan Dardai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoltan Dardai filed Critical Zoltan Dardai
Priority to AU54165/00A priority Critical patent/AU5416500A/en
Publication of WO2001003774A2 publication Critical patent/WO2001003774A2/fr
Publication of WO2001003774A3 publication Critical patent/WO2001003774A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique (y compris vétérinaire) destinée au traitement de la calcification. La composition de l'invention est (a) soit une composition applicable localement (b) soit une composition injectable ou une perfusion, elle comprend en tant que principe actif de l'acide acétyle salicylique soit sous la forme d'un acide libre soit sous la forme de son sel hydrosoluble acceptable sur le plan pharmaceutique, ou de son ester labile biologiquement hydrosoluble et acceptable sur le plan pharmaceutique, avec un excipient, un diluant et/ou un autre agent auxiliaire utilisé de façon classique dans de telles compositions.
PCT/HU2000/000053 1999-07-07 2000-06-02 Composition pharmaceutique de traitement de la calcification WO2001003774A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54165/00A AU5416500A (en) 1999-07-07 2000-06-02 Pharmaceutical composition for the treatment of calcification

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP9902296 1999-07-07
HU9902296A HU9902296D0 (en) 1999-07-07 1999-07-07 Pharmaceutical composition for treating caltification

Publications (2)

Publication Number Publication Date
WO2001003774A2 WO2001003774A2 (fr) 2001-01-18
WO2001003774A3 true WO2001003774A3 (fr) 2002-03-21

Family

ID=89998669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2000/000053 WO2001003774A2 (fr) 1999-07-07 2000-06-02 Composition pharmaceutique de traitement de la calcification

Country Status (3)

Country Link
AU (1) AU5416500A (fr)
HU (1) HU9902296D0 (fr)
WO (1) WO2001003774A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227496B1 (en) * 2001-11-16 2011-07-28 Zoltan Dardai Transdermal pharmaceutical composition containing aspirine for the treatment of sclerosis
US20100099766A1 (en) * 2008-10-16 2010-04-22 Novartis Ag Topical NSAID compositions having sensate component
WO2011076401A1 (fr) 2009-12-23 2011-06-30 Holger Schankin Compositions pharmaceutiques sensiblement exemptes d'eau, contenant de l'acide acétylsalicylique

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE596326A (fr) * 1959-11-02 1961-02-15 Guy Leopold Van Moorleghem Soluté injectable d'aspirine et sou procédé de préparation
GB1036314A (en) * 1962-10-10 1966-07-20 Ile De Rech S Phamaceutiques E Injectable solution of acetylsalicylic acid
FR2295753A1 (fr) * 1974-12-23 1976-07-23 Despin Jean Composition a base d'acide acetyl-salicylique a usage topique
FR2297612A1 (fr) * 1975-01-20 1976-08-13 Moorleghem Guy Van Procede de fabrication d'un produit analgesique a usage externe
JPS53124607A (en) * 1977-04-06 1978-10-31 Fujimoto Seiyaku Kk Novel preparation of aspirin included in dextrine analogue
US4275059A (en) * 1977-03-28 1981-06-23 The Procter & Gamble Company Salicylate anti-inflammatory composition
FR2556218A1 (fr) * 1983-12-12 1985-06-14 Gerard Alain Produit pharmaceutique pour application locale constitue par l'association d'un principe actif medicamenteux-agent enzymatique
US4533551A (en) * 1984-02-17 1985-08-06 American Home Products Corporation Method of treating arthritis with etodolac
JPS6416726A (en) * 1987-07-08 1989-01-20 Teisan Seiyaku Kk Production of aspirin dl-lysine injection
FR2648711A1 (fr) * 1989-05-17 1990-12-28 Jean Blum Complexe soluble dans l'eau et stabilise de l'acide acetyl-salicylique et son procede de fabrication
WO1996028168A1 (fr) * 1993-04-22 1996-09-19 The Hope Heart Institute Methodes de traitement de la thrombose
US5763425A (en) * 1991-04-03 1998-06-09 Gundersen Clinic, Ltd. Suppression of thromboxane levels by percutaneous administration of aspirin
WO2000002565A1 (fr) * 1998-07-09 2000-01-20 Alexander Galat Composition d'acetylsalicylate de sodium injectable et procede afferent

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE596326A (fr) * 1959-11-02 1961-02-15 Guy Leopold Van Moorleghem Soluté injectable d'aspirine et sou procédé de préparation
GB1036314A (en) * 1962-10-10 1966-07-20 Ile De Rech S Phamaceutiques E Injectable solution of acetylsalicylic acid
FR2295753A1 (fr) * 1974-12-23 1976-07-23 Despin Jean Composition a base d'acide acetyl-salicylique a usage topique
FR2297612A1 (fr) * 1975-01-20 1976-08-13 Moorleghem Guy Van Procede de fabrication d'un produit analgesique a usage externe
US4275059A (en) * 1977-03-28 1981-06-23 The Procter & Gamble Company Salicylate anti-inflammatory composition
JPS53124607A (en) * 1977-04-06 1978-10-31 Fujimoto Seiyaku Kk Novel preparation of aspirin included in dextrine analogue
FR2556218A1 (fr) * 1983-12-12 1985-06-14 Gerard Alain Produit pharmaceutique pour application locale constitue par l'association d'un principe actif medicamenteux-agent enzymatique
US4533551A (en) * 1984-02-17 1985-08-06 American Home Products Corporation Method of treating arthritis with etodolac
JPS6416726A (en) * 1987-07-08 1989-01-20 Teisan Seiyaku Kk Production of aspirin dl-lysine injection
FR2648711A1 (fr) * 1989-05-17 1990-12-28 Jean Blum Complexe soluble dans l'eau et stabilise de l'acide acetyl-salicylique et son procede de fabrication
US5763425A (en) * 1991-04-03 1998-06-09 Gundersen Clinic, Ltd. Suppression of thromboxane levels by percutaneous administration of aspirin
WO1996028168A1 (fr) * 1993-04-22 1996-09-19 The Hope Heart Institute Methodes de traitement de la thrombose
WO2000002565A1 (fr) * 1998-07-09 2000-01-20 Alexander Galat Composition d'acetylsalicylate de sodium injectable et procede afferent

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BEKEMEIER H ET AL: "ON STEROID-SAVING DRUG COMBINATIONS IN CARRAGEENIN PAW EDEMA AND ADJUVANT ARTHRITIS", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, EDITIO CANTOR. AULENDORF, DE, vol. 36, no. 10, 1986, pages 1521 - 1524, XP001015554, ISSN: 0004-4172 *
DATABASE WPI Section Ch Week 197849, Derwent World Patents Index; Class B05, AN 1978-88532A, XP002176996 *
DATABASE WPI Section Ch Week 198909, Derwent World Patents Index; Class B05, AN 1989-064967, XP002176997 *
EULERT J ET AL: "HETROTOPE OSSIFIKATIONEN", UNFALLCHIRURGIE, URBAN UND VOGEL, MUNCHEN,, DE, vol. 100, no. 8, August 1997 (1997-08-01), pages 667 - 674, XP001014549, ISSN: 0340-2649 *
KEITEL W: "KOMPLEXTHERAPIE IN DER RHEUMATOLOGIE", ZEITSCHRIFT FUER AERZTLICHE FORTBILDUNG, JENA, DD, vol. 85, no. 9, 1991, pages 410 - 415, XP001015395, ISSN: 0044-2178 *
SAWAR A ET AL: "DRUG THERAPY OF RHEUMATOID ARTHRITIS", DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, J.R. PROUS SS.A. INTERNATIONAL PUBLISHERS, ES, vol. 33, no. 5, June 1997 (1997-06-01), pages 299 - 306, XP001014547, ISSN: 0025-7656 *
SOMOGYI A ET AL: "INHIBITION BY SALICYLATES OF VARIOUS CALCIFYING CONNECTIVE TISSUE REACTIONS", ARCHIVES INTERNATIONALES PHARMACODYNAMIE ET DE THERAPIE, NEW YORK, NY, US, vol. 177, no. 1, 1969, pages 211 - 223, XP001015523, ISSN: 0003-9780 *

Also Published As

Publication number Publication date
AU5416500A (en) 2001-01-30
HU9902296D0 (en) 1999-10-28
WO2001003774A2 (fr) 2001-01-18

Similar Documents

Publication Publication Date Title
CA2411754A1 (fr) Acide 4-¬(4-chloro-2-hydroxybenzoyl)amino|butanoique et compositions d'administration d'agents actifs
IL195055A0 (en) Phenoxy carboxylic acid compounds and compositions for delivering active agents
CA2408142A1 (fr) Inhibiteurs de 11-beta-hydroxy-steroide-deshydrogenase de type 1
CA2370565A1 (fr) Compositions pharmaceutiques contenant de la vitamine d pour application cutanee
CA2258920A1 (fr) Acide hyaluronique autoreticule et compositions pharmaceutiques associees pour le traitement des arthropathies
AU2002214953A1 (en) Pharmaceutical composition for the systematic administration of pharmacologically active ingredients containing polyol fatty acid esters
IE940583L (en) Topical antimicrobial pharmaceutical compositions
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
WO2002019969A3 (fr) Acide (5-(2-hydroxy-4-chlorobenzoyl) aminovalerique et ses sels, compositions contenant l'acide et ses sels pour acheminer des agents actifs
AU2001278696A1 (en) Aqueous pharmaceutical compositions
WO2004010941A3 (fr) Compositions pharmaceutiques de 2,6-diisopropylphenol aqueux
CA2360220A1 (fr) Composes a base d'oxadiazole et compositions destinees a l'apport d'agents actifs
WO2001085139A3 (fr) Vecteur d'administration semi-solide et compositions pharmaceutiques associees
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL155788A (en) A highly purified ifn – β active and mannitol-containing preparation, a method to make an improved stability of ifn – β active, and a method to enhance the stability of ifn – β in biologically active formulation.
WO1996001634B1 (fr) Compositions a base d'oxytretracycline a action prolongee
WO2002100338A3 (fr) Compose et composition permettant d'administrer des principes actifs
WO2001003774A3 (fr) Composition pharmaceutique de traitement de la calcification
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BE2016C017I2 (fr)
BG106368A (en) Pharmaceutical composition and its preparation
EA200200415A1 (ru) Композиция фармацевтического носителя

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载